Hormone Sensitive: Are their studies to... - Advanced Prostate...

Advanced Prostate Cancer

21,446 members26,866 posts

Hormone Sensitive

Blair77 profile image
4 Replies

Are their studies to read on average how long men diagnosed with de novo metastatic disease respond to ADT?

Written by
Blair77 profile image
Blair77
To view profiles and participate in discussions please or .
Read more about...
4 Replies
Tall_Allen profile image
Tall_Allen

About 2 1/2 years median.

pjoshea13 profile image
pjoshea13

You mean ADT as monotherapy? Adding an androgen receptor antagonist, e.g., should increase the time to resistance. There seems to be great interest in combinations & timing now that there are more drugs to work with.

Also, a lipophilic statin plus Avodart block certain avenues of resistance. & I'd add Metformin.

-Patrick

Blair77 profile image
Blair77 in reply to pjoshea13

He had upfront Docetaxel, and is on casodex and Lupron. He just started metformin by coincidence because he has diabeties.

FCoffey profile image
FCoffey

The average is about 2 years but that includes men whose PSA never goes below 20, and men who stay on ADT with PSA well below 1 for 5 or even 10 years. Averages don't tell you much, every patient and every cancer is different.

I agree with Patrick and Nalakrats. Metformin is cheap, safe, and appear to provide significant benefits to at least some men. It is quite rare to be hurt by Metformin.

Avodart (dutasteride) is also well tolerated by most men, and helps block the conversion of any remaining testosterone to DHT, which appears to promote cancer as well as inflammation of the prostate (which promotes cancer.)

I don't have any experience or decent knowledge of androgen receptor antagonists, and I'm deeply suspicious of statins, but that's just me.

You may also like...

Zytiga in the hormone sensitive setting

Zytiga while hormone sensitive

Is my cancer still hormone sensitive?

3 month shot on March 2, 2021, when I started a ADT break. By beginning of September my PSA was 0.10

provenge in the metastatic hormone sensitive PCa patient

could point to clinical trials in its use for the metastatic hormone sensitive APCa patient such as...

Successful PSMA Lu177 treatment of hormone-sensitive PCa

also to support this type of salvage radiation with ADT.